Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Cerevel Therapeutics Holdings, Inc.

NASDAQ

Market Cap.

7.57B

Avg. Volume

1.47M

AI Analyst

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Cerevel Therapeutics Holdings, Inc.!

Still processing it, give me a bit more time...

Cerevel Therapeutics Holdings, Inc. News

Cerevel Therapeutics Holdings, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

HealthcareBiotechnology
cerevel.com

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Cerevel Therapeutics Holdings, Inc. Earnings & Revenue

Cerevel Therapeutics Holdings, Inc. Financials

Table Compare

Compare CERE metrics with:

   

Earnings & Growth

CERE

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

CERE

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

CERE

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

CERE

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Cerevel Therapeutics Holdings, Inc. Income

Cerevel Therapeutics Holdings, Inc. Balance Sheet

Cerevel Therapeutics Holdings, Inc. Cash Flow

Cerevel Therapeutics Holdings, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsSell
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Cerevel Therapeutics Holdings, Inc. Executives

NameRole
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman
Dr. Ramiro Sanchez M.D.Chief Medical Officer
Dr. John J. Renger Ph.D.Chief Scientific Officer
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs Officer
Mr. Mark BodenraderVice President of Finance & Chief Accounting Officer
NameRoleGenderDate of BirthPay
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman19601.14M
Dr. Ramiro Sanchez M.D.Chief Medical Officer1961805.13K
Dr. John J. Renger Ph.D.Chief Scientific Officer1969779.75K
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs OfficerFemale1971600.79K
Mr. Mark BodenraderVice President of Finance & Chief Accounting OfficerMale1973496.17K

Cerevel Therapeutics Holdings, Inc. Insider Trades

Date1 Apr
NameCOLES N ANTHONY
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares50000
Date1 Apr
NameCOLES N ANTHONY
RoleDirector
TransactionDisposed
TypeS-Sale
Shares50000
Date1 Apr
NameCOLES N ANTHONY
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares50000
Date4 Mar
NameCOLES N ANTHONY
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares50000
Date4 Mar
NameCOLES N ANTHONY
RoleDirector
TransactionDisposed
TypeS-Sale
Shares50000
DateNameRoleTransactionTypeShares
1 AprCOLES N ANTHONYDirectorAcquiredM-Exempt50000
1 AprCOLES N ANTHONYDirectorDisposedS-Sale50000
1 AprCOLES N ANTHONYDirectorDisposedM-Exempt50000
4 MarCOLES N ANTHONYDirectorAcquiredM-Exempt50000
4 MarCOLES N ANTHONYDirectorDisposedS-Sale50000

Discover More

Cerevel Therapeutics Holdings, Inc.

NASDAQ

Market Cap.

7.57B

Avg. Volume

1.47M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Cerevel Therapeutics Holdings, Inc. News

Cerevel Therapeutics Holdings, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Cerevel Therapeutics Holdings, Inc. Earnings & Revenue

Cerevel Therapeutics Holdings, Inc. Income

Cerevel Therapeutics Holdings, Inc. Balance Sheet

Cerevel Therapeutics Holdings, Inc. Cash Flow

Cerevel Therapeutics Holdings, Inc. Financials Over Time

Cerevel Therapeutics Holdings, Inc. Executives

NameRole
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman
Dr. Ramiro Sanchez M.D.Chief Medical Officer
Dr. John J. Renger Ph.D.Chief Scientific Officer
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs Officer
Mr. Mark BodenraderVice President of Finance & Chief Accounting Officer
NameRoleGenderDate of BirthPay
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman19601.14M
Dr. Ramiro Sanchez M.D.Chief Medical Officer1961805.13K
Dr. John J. Renger Ph.D.Chief Scientific Officer1969779.75K
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs OfficerFemale1971600.79K
Mr. Mark BodenraderVice President of Finance & Chief Accounting OfficerMale1973496.17K

Cerevel Therapeutics Holdings, Inc. Insider Trades

Date1 Apr
NameCOLES N ANTHONY
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares50000
Date1 Apr
NameCOLES N ANTHONY
RoleDirector
TransactionDisposed
TypeS-Sale
Shares50000
Date1 Apr
NameCOLES N ANTHONY
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares50000
Date4 Mar
NameCOLES N ANTHONY
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares50000
Date4 Mar
NameCOLES N ANTHONY
RoleDirector
TransactionDisposed
TypeS-Sale
Shares50000
DateNameRoleTransactionTypeShares
1 AprCOLES N ANTHONYDirectorAcquiredM-Exempt50000
1 AprCOLES N ANTHONYDirectorDisposedS-Sale50000
1 AprCOLES N ANTHONYDirectorDisposedM-Exempt50000
4 MarCOLES N ANTHONYDirectorAcquiredM-Exempt50000
4 MarCOLES N ANTHONYDirectorDisposedS-Sale50000
HealthcareBiotechnology
cerevel.com

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

AI Analyst

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Cerevel Therapeutics Holdings, Inc.!

Still processing it, give me a bit more time...

Cerevel Therapeutics Holdings, Inc. Financials

Table Compare

Compare CERE metrics with:

   

Earnings & Growth

CERE

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

CERE

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

CERE

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

CERE

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Cerevel Therapeutics Holdings, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsSell
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More